Peer-Review Publications Continue Supporting Auryxia DIfferentiation - Roth Capital (KERX)
Tweet Send to a Friend
Roth Capital affirms Keryx Biopharmaceuticals Inc. (Nasdaq: KERX) at Buy with a price target of $27 after Keryx announced the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
